var data={"title":"Doxycycline: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Doxycycline: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6077?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=doxycycline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Doxycycline: Patient drug information&quot;</a> and <a href=\"topic.htm?path=doxycycline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Doxycycline: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163331\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Acticlate;</li>\n      <li>Adoxa Pak 1/100 [DSC];</li>\n      <li>Adoxa Pak 1/150 [DSC];</li>\n      <li>Adoxa Pak 2/100 [DSC];</li>\n      <li>Adoxa [DSC];</li>\n      <li>Alodox Convenience [DSC];</li>\n      <li>Avidoxy;</li>\n      <li>Doryx;</li>\n      <li>Doryx MPC;</li>\n      <li>Doxy 100;</li>\n      <li>Mondoxyne NL;</li>\n      <li>Monodox [DSC];</li>\n      <li>Morgidox;</li>\n      <li>NicAzelDoxy 30 [DSC];</li>\n      <li>NicAzelDoxy 60 [DSC];</li>\n      <li>Ocudox [DSC];</li>\n      <li>Okebo;</li>\n      <li>Oracea;</li>\n      <li>TargaDOX;</li>\n      <li>Vibramycin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163332\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Doxy;</li>\n      <li>Apo-Doxy Tabs;</li>\n      <li>Apprilon;</li>\n      <li>Dom-Doxycycline;</li>\n      <li>Doxycin;</li>\n      <li>Doxytab;</li>\n      <li>Periostat;</li>\n      <li>PHL-Doxycycline;</li>\n      <li>PMS-Doxycycline;</li>\n      <li>Teva-Doxycycline;</li>\n      <li>Vibramycin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163364\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Tetracycline Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163336\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Doxycycline is available as hyclate, monohydrate, and calcium salts. All doses are expressed as doxycycline base.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> Immediate-release and most extended-release formulations: 100 to 200 mg/day in 1 to 2 divided doses. <b>Note:</b> 120 mg of modified polymer coated tablet (Doryx MPC) is equivalent to 100 mg conventional delayed-release tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV: </i>100 mg every 12 hours. <b>Note: </b>IV form may cause phlebitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acne vulgaris (moderate to severe, inflammatory) (off-label dose): </b>Oral: <b>Note:</b> Use as an adjunct to topical acne therapy (AAD [Zaenglein 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release:</i> 50 to 100 mg twice daily or 100 mg once daily (AAD [Zaenglein 2016]; Graber 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release:</i> 100 mg twice daily on day one, then 100 mg once daily (AAD [Zaenglein 2016]; Graber 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Subantimicrobial dosing:</i> 20 mg twice daily (immediate release) or 40 mg once daily (delayed release) (Moore 2015; Skidmore 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Duration:</i> Use the shortest possible duration to minimize risk of adverse effects and development of bacterial resistance; re-evaluate at 3 to 4 months (AAD [Zaenglein 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anaplasmosis and ehrlichiosis (off-label use)</b>: Oral, IV: 100 mg twice daily for 10 days (IDSA [Wormser 2006]) or at least 3 days after resolution of fever (CDC [Biggs 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax: Note:</b> Consult public health officials for event-specific recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Inhalational exposure (postexposure prophylaxis):</i> Oral: 100 mg every 12 hours for 60 days (CDC [Hendricks 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cutaneous (without systemic involvement), treatment:</i> Oral: 100 mg every 12 hours for 7 to 10 days after naturally acquired infection; treat for 60 days for bioterrorism-related cases (CDC [Hendricks 2014]. <b>Note:</b> Patients with cutaneous lesions of the head or neck or extensive edema should be treated for systemic involvement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Systemic (meningitis excluded; alternative agent), treatment:</i> IV: Initial: 200 mg as a single dose, then 100 mg every 12 hours, in combination with a bactericidal agent; treat for 2 weeks or until clinically stable, whichever is longer. <b>Note:</b> Following a course of IV combination therapy, patients exposed to aerosolized spores require oral doxycycline monotherapy to complete an antimicrobial course of 60 days (CDC [Hendricks 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Bartonella</i></b>\n      <b> spp. </b>\n      <b>infection: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-infected (off-label use):</i>\n      <b> Note: </b>Duration of therapy is at least 3 months; continuation of therapy depends on relapse occurrence and clinical condition (HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bacillary angiomatosis, peliosis hepatis, bacteremia, and osteomyelitis:</i> Oral, IV: 100 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CNS infections:</i> Oral, IV: 100 mg every 12 hours; may add rifampin therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Endocarditis, confirmed:</i> Oral, IV: 100 mg IV every 12 hours in combination with gentamicin for 2 weeks, then continue with doxycycline 100 mg IV or orally every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Other severe infections:</i> Oral, IV: 100 mg every 12 hours in combination with rifampin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-uninfected:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bacteremia without endocarditis: </i>Oral: 200 mg once daily <b>or</b> 100 mg twice daily for 4 weeks with gentamicin once daily for first 2 weeks (Foucault 2003; Rolain 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cat-scratch disease, CNS infection, and neuroretinitis: </i>Oral, IV: 100 mg twice daily in combination with rifampin (Rolain 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Endocarditis, confirmed:</i> Oral: 100 mg every 12 hours for 6 to 12 weeks with gentamicin for first 2 weeks (Rolain 2004; Spach 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bite-wound infection, prophylaxis or treatment (animal and human bites; alternative agent) (off-label use):</b> Oral, IV: 100 mg twice daily. Duration is 3 to 5 days for prophylaxis; duration of treatment for established infection varies based on patient-specific factors (IDSA [Stevens 2014]). <b> Note:</b> Some experts use in combination with an appropriate agent for anaerobes (Harper 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brucellosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocarditis or neurobrucellosis: Limited data available: IV, Oral: 100 mg twice daily as part of a combination regimen (Bosivkolski 2017; Jia 2017; Zheng 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Uncomplicated (non-focal): Oral: 100 mg twice daily plus rifampin for 6 weeks <b>or </b>100 mg twice daily for 6 weeks plus gentamicin for the first 5 to 14 days (Ariza 2007; Hasanjani Roushan 2006; Skalsky 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Spondylitis: Oral: 100 mg twice daily for at least 12 weeks plus streptomycin for the first 14 to 21 days (Skalsky 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Postexposure prophylaxis (high-risk laboratory exposure):</i> Oral: 100 mg twice daily with rifampin for 3 weeks (CDC 2012); for exposure to <i>B. abortus</i> RB51 strains, some experts give doxycycline plus trimethoprim-sulfamethoxazole (Bosilkovski 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cellulitis, mild to moderate (outpatient treatment; empiric coverage of MRSA) (off-label use):</b> Oral: 100 mg twice daily for 5 to 14 days (IDSA [Liu 2011; Stevens 2014]). <b>Note:</b> For empiric therapy of non-purulent cellulitis, an additional agent (eg, amoxicillin, cephalexin) for coverage of beta-hemolytic streptococci is needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cholera (<i>Vibrio cholerae</i>), treatment (adjunctive therapy for severely ill patients): </b>Oral: 300 mg as a single dose. <b>Note</b>: Due to resistance concerns, antimicrobial therapy during an outbreak or epidemic should be guided by isolate susceptibility (CDC 2015; WHO 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lyme disease (<i>Borrelia</i> spp. infection) (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prophylaxis:</i> 200 mg single dose. <b>Note:</b> Prophylaxis is used only in patients who meet <b>all</b> of the following criteria: Deer tick attached for &ge;36 hours, prophylaxis can be given within 72 hours of tick removal, local rate of deer tick infection with <i>Borrelia burgdorferi</i> is &ge;20%, and there are no contraindications to doxycycline (Hu 2017; IDSA [Wormser 2006]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment, early localized (eg, erythema migrans):</i> 100 mg twice daily for 10 to 21 days (IDSA [Wormser 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment, arthritis without neurologic involvement (early or late disease)</i>: 100 mg twice daily for 28 days (Hu 2017; IDSA [Wormser 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment, early disseminated, mild neurologic involvement (isolated facial nerve palsy): </i>100 mg twice daily for 14 to 28 days (Hu 2017; Wormser 2006). <b>Note: </b>Not recommended for serious neurologic disease (Hu 2017; IDSA [Wormser 2006]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malaria:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chemoprophylaxis in travelers</i>\n      <b>:</b> Oral (immediate release and delayed release): 100 mg daily; initiate 1 to 2 days prior to travel to endemic area; continue daily during travel and for 4 weeks after leaving endemic area.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Uncomplicated malaria, treatment (chloroquine resistant or unknown resistance; alternative agent) (off-label use):</i> Oral: 100 mg twice daily for 7 days in combination with quinine sulfate (plus primaquine for <i>Plasmodium vivax</i>). <b>Note:</b> Quinine sulfate duration is region specific; consult CDC for current recommendations (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Severe malaria, treatment (alternative agent) (off-label use):</i> IV, Oral: 100 mg every 12 hours for 7 days in combination with quinidine gluconate. <b>Note:</b> IV therapy should be administered for at least 24 hours or until oral medication tolerated; quinidine gluconate duration is region specific; consult CDC for current recommendations (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Periodontitis, chronic:</b> Oral: 20 mg (subantimicrobial dose) twice daily for 3 to 9 months as an adjunct to scaling and root planing (Smiley 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plague <i>(Yersinia pestis</i>)</b> <b>(alternative agent):</b> Oral, IV: 200 mg initially then 100 mg twice daily <b>or</b> 200 mg once daily for 10 to 14 days and at least until 2 days after patient has defervesced (CDC 2015; IDSA [Stevens 2014]; Inglesby 2000; Sexton 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pleurodesis, chemical (sclerosing agent for pleural effusion; off label use): </b>Intrapleural: 500 mg as a single dose in 30 to 100 mL NS (Porcel 2006; Robinson 1993); may require a repeat dose (Kvale 2007); some experts combine with or administer following instillation of a local anesthetic (eg, lidocaine, 10 mL [100 mg] of 1% solution [Robinson 1993] or mepivacaine 20 mL [400 mg] of 2% solution [Porcel 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired</b> <b>(alternative agent)</b>: Outpatients or inpatients (non-ICU): Oral, IV: 100 mg twice daily for 5 to 7 days. For empiric therapy of inpatients, use in combination with another appropriate agent (eg, antipneumococcal beta-lactam) (ATS/IDSA [Mandell 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection (off-label use):</b> Treatment (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Duration ranges from a minimum of 3 months to indefinitely, depending on patient-specific factors (Berbari 2018).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Staphylococci: </i>100 mg twice daily. For the first 3 to 6 months of therapy, combine with rifampin (Berbari 2018; IDSA [Osmon 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cutibacterium acnes (alternative agent)</i>: 100 mg twice daily (IDSA [Osmon 2013]; Kanafani 2018).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Q fever:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute:</i> 100 mg every 12 hours for 14 days (CDC [Anderson 2013]). <b>Note:</b> In patients with valvulopathy/cardiomyopathy, some experts recommend extending treatment to 12 months in combination with hydroxychloroquine to prevent progression to persistent infection (Million 2013; Raoult 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Persistent localized infection (endocarditis, vascular infection):</i> Oral: 100 mg every 12 hours in combination with hydroxychloroquine for &ge;18 months depending on site of infection and serologic response (CDC [Anderson 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rhinosinusitis, acute bacterial (alternative agent for beta-lactam intolerance; off-label use):</b> Oral: 200 mg/day in 1 to 2 divided doses for 5 to 7 days (IDSA [Chow 2012]). <b>Note:</b> In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients (Harris 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rocky Mountain spotted fever:</b> Oral, IV: 100 mg twice daily for 5 to 7 days or for at least 3 days after fever subsides, whichever is longer; initiate treatment as soon as possible. Severe or complicated disease may require longer treatment (CDC [Biggs 2016]). <b>Note:</b> A loading dose of 200 mg IV is recommended for critically ill patients (Sexton 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rosacea, moderate to severe or unresponsive to topical therapy: </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Traditional dosing (off-label dose): </i>Initial: 50 to 100 mg twice daily for 4 to 12 weeks; may follow with a topical agent and/or subantimicrobial doxycycline dosing for long-term management. Alternatively, may initiate therapy with subantimicrobial dosing (Maier 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Subantimicrobial dosing:</i> 40 mg once daily (delayed-release; Oracea) or 20 mg twice daily (immediate release) (Sanchez 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sexually transmitted infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Epididymitis, acute (off-label use): Empiric or pathogen-directed therapy for chlamydia and/or gonorrhea:</i> Oral: 100 mg twice daily for 10 days with single dose ceftriaxone (CDC [Workowski 2015]).<b> Note: </b>An alternative regimen is recommended in patients whose sexual practices increase risk of infection with enteric pathogens (Eyre 2017; Marrazzo 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Granuloma inguinale </i>(Donovanosis) (alternative agent): Oral: 100 mg twice daily for at least 3 weeks and until all lesions have healed. <b>Note:</b> If symptoms do not improve within the first few days of therapy, another agent (eg, aminoglycoside) can be added (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lymphogranuloma venereum</i> (LGV): Oral: 100 mg twice daily for 21 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pelvic inflammatory disease (off-label use):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inpatient (severe PID): IV, Oral: 100 mg every 12 hours in combination with cefoxitin or cefotetan; transition to oral therapy after &gt;24 hours improvement to complete a 14 day total course. If pelvic abscess, anaerobic coverage is warranted (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Outpatient (mild to moderate PID): Oral: 100 mg every 12 hours for 14 days in combination with single-dose ceftriaxone (preferred) (Wiesenfeld 2017) <b>or</b> single dose of cefoxitin plus oral probenecid or other third generation cephalosporin; if <i>Trichomonas vaginalis</i> or recent uterine instrumentation, add metronidazole (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Proctitis, acute or proctocolitis (off-label use): Empiric or pathogen-directed therapy for chlamydia and/or gonorrhea:</i> Oral: 100 mg twice daily for 7 days plus single dose ceftriaxone. <b>Note:</b> Provide 21 days of doxycycline if PCR for LGV confirmed or as presumptive therapy for LGV if patient has severe rectal symptoms (eg, bloody discharge, perianal ulcers, or mucosal ulcers), and either a positive rectal chlamydia NAAT or HIV infection. Additional coverage for herpes simplex virus is warranted in patients with perianal or mucosal ulcers (CDC [Workowski 2015], Zenilman 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cervicitis or urethritis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chlamydia trachomatis:</i> Oral: 100 mg twice daily for 7 days (CDC [Workowski 2015]) <b>or</b> 200 mg delayed-release once daily for 7 days (Geisler 2012); consider concurrent treatment for gonorrhea with single dose ceftriaxone based on individual risk factors, if local prevalence is elevated (&gt;5%), or if intracellular gram-negative diplococci on Gram stain (CDC [Workowski 2015]; Marrazzo 2017). <b>Note: </b>Directly observed single dose azithromycin is preferred for the treatment of uncomplicated genital chlamydial infections by some experts (Marrazzo 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Neisseria gonorrhea </i>(alternative agent [due to resistance]; reserve for patients with azithromycin intolerance): Oral: 100 mg twice daily for 7 days in combination with a single dose of ceftriaxone (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Syphilis, penicillin-allergic patients: </i>\n      <b>Note:</b> Limited data support use of alternatives to penicillin and close serologic and clinical follow up is warranted (CDC [Workowski 2015]; Hicks 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Early syphilis (primary, secondary, and early latent): Oral: 100 mg twice daily for 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Late syphilis (late latent): Oral: 100 mg twice daily for 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical prophylaxis, pregnancy termination (dilation and evacuation procedure) (off-label use): </b>Oral: 100 mg 1 hour prior to procedure, followed by 200 mg after the procedure (ACOG 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tularemia (<i>Francisella tularensis</i>):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment (mild infection):</i> Oral: 100 mg twice daily for &ge;14 days (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Postexposure prophylaxis (non-bioterrorism event, high-risk exposure):</i> Oral: 100 mg twice daily for 14 days (Penn 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Bioterrorism event:</i> <b>Note:</b> Consult public health officials for event-specific recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mass casualty management or postexposure prophylaxis (when used as a biological weapon): Oral: 100 mg twice daily for 14 days (Dennis 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Contained casualty management (when used as a biological weapon): IV (may transition to oral if clinically appropriate): 100 mg every 12 hours for 14 to 21 days (Dennis 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163349\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=doxycycline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Doxycycline: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate and delayed-release:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;8 years and Adolescents (&lt;45 kg): Oral, IV: 2 to 4 mg/kg/day in 1 to 2 divided doses, not to exceed 200 mg/day (AAP [Red Book] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;8 years and Adolescents (&ge;45 kg): Oral, IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anaplasmosis and ehrlichiosis (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;8 years: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;45 kg: 2.2 mg/kg/dose (maximum dose: 100 mg/dose) every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Duration of therapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If co-infection with Lyme disease is not suspected, may treat for at least 3 days after fever subsides and clinical improvement is noted; typical minimum duration of therapy is 5 to 7 days (CDC [Biggs 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If co-infection with Lyme disease is suspected, treat for 10 days (CDC [Biggs 2016]) or, alternatively, treat with a short course of doxycycline (4 to 5 days [ie, ~3 days after resolution of fever]) and start an antimicrobial with efficacy against <i>Borrelia burgdorferi </i>(eg, amoxicillin, cefuroxime) at the end of the doxycycline course to complete 14 days of total treatment (IDSA [Wormser 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;8 years and Adolescents: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;45 kg: 2.2 mg/kg/dose (maximum dose: 100 mg/dose) every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Duration of therapy:</i> 10 days to provide appropriate length of therapy for possible co-infection with Lyme disease (CDC [Biggs 2016]; IDSA [Wormser 2006]) or, alternatively, add another antimicrobial with efficacy against <i>Borrelia burgdorferi</i> (CDC [Biggs 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;45 kg: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Bartonella </i></b> <b>infection: HIV-infected patients (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chlamydial infections, uncomplicated:</b> Children &ge;8 years (and &gt;45 kg) and Adolescents: Oral: <i>US labeling:</i> 100 mg twice daily for 7 days; alternatively, for endocervical or urethral infections, may give 200 mg delayed-release tablet once daily for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lyme disease (<i>Borrelia</i> spp. infection) (off-label use):</b> Children &ge;8 years: Oral (Halperin 2007; Wormser 2006):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prophylaxis:</i> 4 mg/kg (maximum: 200 mg) administered as a single dose; <b>Note:</b> Initiate within 72 hours of tick removal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment (early Lyme disease without neurologic manifestations):</i> 1 to 2 mg/kg twice daily for 10 to 21 days (maximum: 100 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment (meningitis and other early neurologic manifestations):</i> 4 to 8 mg/kg/day in 2 divided doses for 10 to 28 days (maximum: 200 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malaria:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chemoprophylaxis in travelers:</i> Children &ge;8 years: Oral: 2.2 mg/kg/dose once daily (maximum dose: 100 mg/day) starting 1 to 2 days before travel to the area with endemic infection, continuing daily during travel and for 4 weeks after leaving endemic area; maximum duration of prophylaxis: 4 months (CDC [Arguin 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Severe malaria, treatment (off-label use): </i>Children &ge;8 years: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;45 kg: 2.2 mg/kg (maximum dose: 100 mg) every 12 hours for 7 days with quinidine gluconate. <b>Note:</b> Quinidine gluconate duration is region specific; consult CDC for current recommendations (CDC 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;45 kg: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Uncomplicated malaria, treatment (chloroquine resistant or unknown resistance) (off-label use): </i>Children &ge;8 years: Oral: 2.2 mg/kg (maximum dose: 100 mg) every 12 hours for 7 days with quinine sulfate. <b>Note:</b> Quinine sulfate duration is region specific, consult CDC for current recommendations (CDC 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired (CAP):</b> Children &gt;7 years: Oral: <b>Note:</b> A beta-lactam antibiotic should be added if typical bacterial pneumonia cannot be ruled out.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Presumed atypical, mild atypical (<i>M. pneumoniae, C. pneumoniae, C. trachomatis</i>) infection or step-down therapy (alternative to azithromycin): 2 to 4 mg/kg/day in 2 divided doses (maximum: 200 mg/day) (IDSA/PIDS [Bradley 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Q fever:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;8 years with high-risk criteria (eg, hospitalized or have severe illness, with preexisting heart valvulopathy, immunocompromised, or with delayed Q fever diagnosis who have experienced illness for &gt;14 days without resolution of symptoms): 2.2 mg/kg/dose (maximum: 100 mg per dose) twice daily for 14 days (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;8 years with mild or uncomplicated illness: 2.2 mg/kg/dose (maximum: 100 mg per dose) twice daily for 5 days. If patient remains febrile past 5 days of treatment, switch to sulfamethoxazole and trimethoprim (CDC 2013). <b>Note:</b> Some clinicians may recommend initial treatment with sulfamethoxazole and trimethoprim for children &lt;8 years with mild or uncomplicated illness (Hartzell 2008; CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;8 years and Adolescents: 2.2 mg/kg/dose (maximum: 100 mg per dose) twice daily for 14 days (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic:</i> ID consult recommended for treatment of chronic Q fever (CDC 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rocky Mountain spotted fever:</b> Children and Adolescents: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;45 kg: 2.2 mg/kg/dose (maximum dose: 100 mg) every 12 hours; continue treatment for at least 3 days after fever subsides and clinical improvement is noted (typical minimum duration of therapy is 5 to 7 days; severe or complicated disease may require longer treatment) (CDC [Biggs 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;45 kg: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue infections due to MSSA or MRSA (off-label use): </b> Children &ge; 8 years: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&le;45 kg: 2 mg/kg every 12 hours (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;45 kg: 100 mg twice daily (IDSA [Liu 2011]; IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tularemia (when used as a biological weapon) (off-label use) (Dennis 2001):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mass casualty management or postexposure prophylaxis: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;45 kg: 2.2 mg/kg twice daily for 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;45 kg: 100 mg twice daily for 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Contained casualty management: IV (may transition to oral if clinically indicated):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;45 kg: 2.2 mg/kg twice daily for 14 to 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;45 kg: 100 mg every 12 hours for 14 to 21 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163337\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163338\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dialysis: Poorly dialyzed (0% to 5%); no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15804929\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163303\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hyclate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Morgidox: 50 mg, 100 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vibramycin: 100 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as monohydrate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adoxa: 150 mg [DSC] [contains fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mondoxyne NL: 50 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mondoxyne NL: 75 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mondoxyne NL: 100 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Monodox: 75 mg [DSC], 100 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Okebo: 75 mg, 100 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 75 mg, 100 mg, 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral, as monohydrate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oracea: 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Combination, as hyclate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alodox Convenience: 20 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Morgidox: 1 x 50 mg, 2 x 100 mg, 1 x 100 mg [contains brilliant blue fcf (fd&amp;c blue #1), cetyl alcohol, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ocudox: 50 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Oral, as monohydrate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NicAzelDoxy 30: 100 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 (sunset yellow), fd&amp;c yellow #6 aluminum lake, tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NicAzelDoxy 60: 100 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 (sunset yellow), fd&amp;c yellow #6 aluminum lake, tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as hyclate [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doxy 100: 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral, as monohydrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/5 mL (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral, as monohydrate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vibramycin: 25 mg/5 mL (60 mL) [contains brilliant blue fcf (fd&amp;c blue #1), methylparaben, propylparaben; raspberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/5 mL (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral, as calcium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vibramycin: 50 mg/5 mL (473 mL) [contains butylparaben, propylene glycol, propylparaben, sodium metabisulfite; raspberry-apple flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hyclate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acticlate: 75 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acticlate: 150 mg [scored; contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TargaDOX: 50 mg [contains fd&amp;c blue #2 (indigotine), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg, 75 mg, 100 mg, 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as monohydrate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adoxa: 50 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adoxa: 75 mg [DSC] [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adoxa: 100 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adoxa Pak 1/100: 100 mg [DSC] [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adoxa Pak 2/100: 100 mg [DSC] [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adoxa Pak 1/150: 150 mg [DSC] [scored; contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Avidoxy: 100 mg [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 75 mg, 100 mg, 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral, as hyclate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doryx: 50 mg, 150 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doryx: 200 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doryx MPC: 120 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 75 mg, 100 mg, 150 mg, 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163288\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23449398\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alodox Convenience kits contain doxycycline tablets 20 mg, plus eyelid cleanser</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morgidox kits contain doxycycline capsules 100 mg, plus AcuWash moisturizing Daily Cleanser</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NizAzel Doxy kits contain doxycycline tablets 100 mg, plus NicAzel FORTE dietary supplement tablets</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocudox kits contain doxycycline capsules 50 mg, plus eyelid cleanser and Tears Again Advanced eyelid spray</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20303059\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, oral, as monohydrate [strength expressed as base]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apprilon: 40 mg [30 mg (immediate release) and 10 mg (delayed release)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, oral, as hyclate [strength expressed as base]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Periostat: 20 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163306\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral administration is preferable unless patient has significant nausea and vomiting; IV and oral routes are bioequivalent.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: In general, administer with meals to decrease GI upset; however, some manufacturer labeling recommends administration on an empty stomach (see below). Administer capsules and tablets with at least 8 ounces (240 mL) of water and have patient sit up for at least 30 minutes after taking to reduce the risk of esophageal irritation and ulceration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acticlate: Swallow capsule whole; do not break, open, crush, dissolve, or chew. The 150 mg tablet may be broken into 2/3 or 1/3 to provide a 100 mg and 50 mg strength, respectively.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Doxycycline 20 mg tablet, Oracea, Apprilon [Canadian product]: Administer on an empty stomach 1 hour before or 2 hours after meals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Doryx: May be administered by carefully breaking up the tablet and sprinkling tablet contents on a spoonful of cold applesauce. The delayed-release pellets must not be crushed or damaged when breaking up tablet. Should be administered immediately after preparation and without chewing; follow with a cool 8-ounce (240 mL) glass of water to ensure complete swallowing. If applesauce/pellet mixture is not administered immediately, discard (do not store for future use).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Doryx MPC: Do not chew or crush tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Periostat [Canadian product]: Administer 1 hour before breakfast and evening meal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse IV doxycycline over 1 to 4 hours. Avoid extravasation. Prolonged IV administration may cause thrombophlebitis. Oral administration is preferable unless patient has significant nausea and vomiting; IV and oral routes are bioequivalent.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrapleural (off-label route): Instill diluted doxycycline (combined with or following instillation of a local anesthetic) into chest tube; clamp chest tube for 2 hours (Porcel 2006; Robinson 1993).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163304\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acne: </b>Adjunctive therapy in severe acne.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Actinomycosis: </b>Treatment of actinomycosis caused by <i>Actinomyces israelii</i> when penicillin is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute intestinal amebiasis: </b>Adjunct to amebicides in acute intestinal amebiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax, including inhalational anthrax (postexposure): </b>Treatment of anthrax caused by <i>Bacillus anthracis</i>, including inhalational (postexposure) prophylaxis; to reduce the incidence or progression of disease following exposure to aerosolized <i>B. anthracis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cholera: </b>Treatment of cholera infections caused by <i>Vibrio cholerae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Clostridium: </b></i>Treatment of infections caused by <i>Clostridium</i> spp. when penicillin is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gram-negative infections: </b>Treatment of infections caused by <i>Escherichia coli</i>, <i>Enterobacter aerogenes</i>, <i>Shigella</i> spp., <i>Acinetobacter</i> spp., <i>Klebsiella</i> spp. (respiratory and urinary infections), and <i>Bacteroides</i> spp.; <i>Neisseria meningitidis</i> (when penicillin is contraindicated).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gram-positive infections: </b>Treatment of infections caused by <i>Streptococcus</i> spp., when susceptible.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Listeriosis: </b>Treatment of listeriosis due to <i>Listeria monocytogenes</i> when penicillin is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malaria prophylaxis: </b>Prophylaxis of malaria due to <i>Plasmodium falciparum</i> in short-term travelers (under 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine-resistant strains.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mycoplasma pneumoniae: </b>Treatment of infections caused by <i>Mycoplasma pneumoniae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ophthalmic infections: </b>Treatment of inclusion conjunctivitis or trachoma caused by <i>Chlamydia trachomatis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Periodontitis (20 mg tablet and capsule [Periostat (Canadian product)] only): </b>Adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Relapsing fever: </b>Treatment of relapsing fever caused by <i>Borrelia recurrentis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Respiratory tract infections: </b>Treatment of respiratory infections caused by <i>Haemophilus influenzae</i>, <i>Klebsiella</i> spp., or <i>Mycoplasma pneumoniae</i>; treatment of upper respiratory tract infections caused by <i>Streptococcus pneumoniae</i>; respiratory infections caused by <i>Staphylococcus aureus</i> (doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rickettsial infections: </b>Treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by <i>Rickettsiae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rosacea (Oracea, Apprilon [Canadian product] only): </b>Treatment of only inflammatory lesions (papules and pustules) of rosacea in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sexually transmitted infections: </b>Treatment of lymphogranuloma venereum and uncomplicated urethral, endocervical, or rectal infections caused by <i>Chlamydia trachomatis</i>; granuloma inguinale (donovanosis) caused by <i>Klebsiella granulomatis</i>; chancroid caused by <i>Haemophilus ducreyi</i>; nongonococcal urethritis caused by <i>Ureaplasma urealyticum</i>; when penicillin is contraindicated, uncomplicated gonorrhea caused by <i>Neisseria gonorrhea</i> and syphilis caused by <i>Treponema pallidum.</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The CDC sexually transmitted disease guidelines recommend dual antimicrobial therapy be used for uncomplicated gonorrhea due to <i>N. gonorrhea </i>resistance concerns; ceftriaxone is the preferred cephalosporin and doxycycline is an alternate option for the second antimicrobial only in cases azithromycin allergy (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections (Avidoxy only): </b>Treatment of skin and skin structure infections caused by <i>Staphylococcus aureus</i> (doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vincent infection: </b>Treatment of Vincent infection caused by <i>Fusobacterium fusiforme</i> when penicillin is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Yaws: </b>Treatment of yaws caused by <i>Treponema pallidum</i> subspecies <i>pertenue</i> when penicillin is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Zoonotic infections: </b>Treatment of psittacosis (ornithosis) caused by <i>Chlamydophila psittaci</i>; plague due to <i>Yersinia pestis</i>; tularemia caused by <i>Francisella tularensis</i>; brucellosis caused by <i>Brucella</i> spp. (in conjunction with streptomycin); bartonellosis caused by <i>Bartonella bacilliformis</i>; infections caused by <i>Campylobacter fetus</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25473208\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Anaplasmosis and ehrlichiosis; Bartonella infections in HIV-infected patients (adolescents and adults); Bite-wound infection (animal and human bites); Cellulitis, mild to moderate; Epididymitis, acute; Lyme disease (Borrelia spp. infection); Malaria, treatment; Pelvic inflammatory disease; Pleurodesis, chemical (sclerosing agent for pleural effusion); Proctitis, acute or proctocolitis; Prosthetic joint infection; Rhinosinusitis, acute bacterial (ABRS); Surgical prophylaxis, pregnancy termination (dilation and evacuation procedure)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163372\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Doxycycline may be confused with dicyclomine, doxepin, doxylamine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Doxy100 may be confused with Doxil</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Monodox may be confused with Maalox</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Oracea may be confused with Orencia</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vibramycin may be confused with vancomycin, Vibativ</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Oracea (US brand name) is marketed in Canada under the brand name Apprilon</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163295\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety (2%), pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased lactate dehydrogenase (2%), increased serum glucose (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (5%), upper abdominal pain (2%), abdominal distention (1%), abdominal pain (1%), xerostomia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Fungal infection (2%), influenza (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (5%), sinusitis (3%), nasal congestion (2%), sinus headache (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin hyperpigmentation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Esophageal ulcer, esophagitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, anaphylaxis, angioedema, anorexia, bulging fontanel, <i>Clostridium difficile </i>associated diarrhea, dental discoloration, DRESS syndrome, dysphagia, enamel hypoplasia, enterocolitis, eosinophilia, erythema multiforme, erythematous rash, exacerbation of systemic lupus erythematosus, exfoliative dermatitis, glossitis, headache, hemolytic anemia, hepatotoxicity, hypersensitivity reaction, increased blood urea nitrogen (dose related), increased serum ALT, inflammatory anogenital lesion, intracranial hypertension, maculopapular rash, nausea, neutropenia, pancreatitis, pericarditis, pseudomembranous colitis, serum sickness, skin hyperpigmentation, skin photosensitivity, Stevens-Johnson syndrome, thrombocytopenia, thyroid disease (brown/black discoloration; no dysfunction reported), toxic epidermal necrolysis, urticaria, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163310\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to doxycycline, other tetracyclines, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Periostat, Apprilon [Canadian products]: Additional contraindications: Use in infants and children &lt;8 years of age or during second or third trimester of pregnancy; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163292\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI inflammation/ulceration: Esophagitis and ulcerations (sometimes severe) may occur; patients with dysphagia and/or retrosternal pain may require assessment for esophageal lesions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Rarely occurs; if symptomatic, assess LFTs and discontinue drug.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity syndromes: Severe skin reactions (eg, exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms [DRESS]) have been reported. Discontinue therapy for serious hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased BUN: May be associated with increases in BUN secondary to antianabolic effects; this does not occur with use of doxycycline in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intracranial hypertension: Intracranial hypertension (pseudotumor cerebri) has been reported; headache, blurred vision, diplopia, vision loss, and/or papilledema may occur. Women of childbearing age who are overweight or have a history of intracranial hypertension are at greater risk. Intracranial hypertension typically resolves after discontinuation of treatment; however, permanent visual loss is possible. If visual symptoms develop during treatment, prompt ophthalmologic evaluation is warranted. Intracranial pressure can remain elevated for weeks after drug discontinuation; monitor patient until stable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: May cause photosensitivity; discontinue at first sign of skin erythema. Use skin protection and avoid prolonged exposure to sunlight and ultraviolet light.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tissue hyperpigmentation: May induce hyperpigmentation in many organs, including nails, bone, skin (diffuse pigmentation as well as over sites of scars and injury), eyes, thyroid, visceral tissue, oral cavity (adult teeth, mucosa, alveolar bone), sclerae, and heart valves independently of time or amount of drug administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral candidiasis: Safety and effectiveness have not been established for treatment of periodontitis in patients with coexistent oral candidiasis; use with caution in patients with a history or predisposition to oral candidiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May cause tissue hyperpigmentation, tooth enamel hypoplasia, or permanent tooth discoloration (more common with long-term use, but observed with repeated, short courses) when used during tooth development (last half of pregnancy, infancy, and childhood &le;8 years of age); manufacturer states to use in children &le;8 years of age only when the potential benefits outweigh the risks in severe or life threatening conditions (eg, anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies. Limited use between 6 to 7 years of age has minimal effect on the color of permanent incisors (CDC 2006). Recommended in treatment of anthrax exposure (CDC 2001), tickborne rickettsial diseases (CDC 2006), and Q fever (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oracea, Apprilon [Canadian product]: Should not be used for the treatment or prophylaxis of bacterial infections because the lower dose of drug per capsule may be subefficacious and promote resistance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfite sensitivity: Syrup may contain sodium metabisulfite, which may cause allergic reactions in certain individuals (eg, asthmatic patients).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Acne: The American Academy of Dermatology acne guidelines recommend doxycycline as adjunctive treatment for moderate and severe acne and forms of inflammatory acne that are resistant to topical treatments. Concomitant topical therapy with benzoyl peroxide or a retinoid should be administered with systemic antibiotic therapy (eg, doxycycline) and continued for maintenance after the antibiotic course is completed (AAD [Zaenglein 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Limitations of use: Malaria prophylaxis: Doxycycline does not completely suppress asexual blood stages of <i>Plasmodium</i> strains; does not suppress <i>P. falciparum's</i> sexual blood stage gametocytes. Patients completing a regimen may still transmit the infection to mosquitoes outside endemic areas.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163358\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163297\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9393&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Tetracyclines. Management: Separate administration of antacids and oral tetracycline derivatives by several hourse when possible to minimize the extent of this potential interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Doxycycline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subcitrate: May decrease the serum concentration of Tetracyclines. Management: Avoid administration of oral tetracyclines within 30 minutes of bismuth subcitrate administration.  This is of questionable significance for at least some regimens intended to treat H. pylori infections.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subsalicylate: May decrease the serum concentration of Tetracyclines. Management: Consider dosing tetracyclines 2 hours before or 6 hours after bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the serum concentration of Tetracyclines. Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Doxycycline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Doxycycline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Tetracyclines may decrease the absorption of Iron Salts. Iron Salts may decrease the serum concentration of Tetracyclines. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Tetracyclines. Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Dimecrotate: May interact via an unknown mechanism with Tetracyclines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Tetracyclines may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Tetracyclines may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mipomersen: Tetracyclines may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracyclines. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Tetracyclines. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Tetracyclines may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: Tetracyclines may diminish the therapeutic effect of Penicillins. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Doxycycline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinapril: May decrease the serum concentration of Tetracyclines. Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Retinoic Acid Derivatives: Tetracyclines may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern. <b> Exceptions: </b>Adapalene; Bexarotene (Topical); Tretinoin (Topical).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Doxycycline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: May decrease the serum concentration of Tetracyclines. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the absorption of Tetracyclines. Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucroferric Oxyhydroxide: May decrease the serum concentration of Tetracyclines. Management: Administer oral/enteral doxycycline at least 1 h before sucroferric oxyhydroxide.  Specific dose separation guidelines for other tetracyclines are not presently available.  No interaction is anticipated with parenteral administration of tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Tetracyclines may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163326\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethanol: Chronic ethanol ingestion may reduce the serum concentration of doxycycline.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Food: Doxycycline serum levels may be slightly decreased if taken with high-fat meal or milk. Administration with iron or calcium may decrease doxycycline absorption. May decrease absorption of calcium, iron, magnesium, zinc, and amino acids. Management: Administer Doryx and Doryx MPC without regard to meals. Administer Oracea and doxycycline 20 mg tablet on an empty stomach 1 hour before or 2 hours after meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163300\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163313\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Tetracyclines cross the placenta (Mylonas 2011). Therapeutic doses of doxycycline during pregnancy are unlikely to produce substantial teratogenic risk, but data are insufficient to say that there is no risk. In general, reports of exposure have been limited to short durations of therapy in the first trimester. Tetracyclines accumulate in developing teeth and long tubular bones (Mylonas 2011). Permanent discoloration of teeth (yellow, gray, brown) can occur following in utero exposure and is more likely to occur following long-term or repeated exposure.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Doxycycline is the recommended agent for the treatment of Rocky Mountain spotted fever (RMSF) in pregnant women (CDC [Biggs 2016]). For other indications, many guidelines consider use of doxycycline to be contraindicated during pregnancy, or to be a relative contraindication in pregnant women if other agents are available and appropriate for use (Anderson 2013; CDC 2011; HHS [OI adult 2015]; Stevens 2014; Workowski [CDC 2015]; IDSA [Wormser 2006]). Doxycycline should not be used for the treatment of rosacea in pregnant women. When systemic antibiotics are needed for dermatologic conditions, other agents are preferred (Kong 2013; Murase 2014). As a class, tetracyclines are generally considered second-line antibiotics in pregnant women and their use should be avoided (Mylonas 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3415107\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Doxycycline is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of doxycycline is 6.14% when calculated using the highest average breast milk concentration located and compared to an infant therapeutic dose of 4.4 mg/kg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID is &lt;10%; when an RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Using the highest average milk concentration (1.8 mcg/mL), the estimated daily infant dose via breast milk is 0.27 mg/kg/day. This milk concentration was obtained following maternal administration of a single oral dose of doxycycline 200 mg (Tokuda 1969). Concentrations of doxycycline in breast milk may increase with duration of therapy (Anderson 1991).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Oral absorption of doxycycline is not markedly influenced by simultaneous ingestion of milk; therefore, oral absorption of doxycycline by the breastfeeding infant would not be expected to be diminished by the calcium in the maternal milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The therapeutic use of doxycycline should be avoided during tooth development (children &lt;8 years) unless there are no alternative therapies due to the potential for tissue hyperpigmentation, tooth enamel hypoplasia, or permanent tooth discoloration. Theoretically, this risk is also present in breastfeeding infants exposed to doxycycline via breast milk. Although breastfeeding is not specifically contraindicated, the effects of long-term exposure via breast milk are not known. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. The World Health Organization (WHO) states that maternal use of doxycycline should be avoided if possible but that a single dose or the short-term use of doxycycline is probably safe; there exists a possibility of dental staining and inhibition of bone growth in the infant, especially with prolonged use (WHO 2002). In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush and diarrhea (WHO 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Current guidelines note that the short-term use of doxycycline for the treatment of RMSF is considered compatible with breastfeeding (CDC [Biggs 2016]). However, breastfeeding is a relative contraindication for the use of doxycycline in the treatment of Lyme disease (Wormser 2006). If used for the treatment or prophylaxis of malaria, breastfeeding during doxycycline therapy is considered compatible; however, the theoretical risk of dental staining and inhibition of long bone growth in the breastfeeding infant should be considered (WHO 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Long-term use of tetracyclines (eg, for the treatment of acne) should be avoided in breastfeeding women (Pugashetti 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163314\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines (in general): Take with food if gastric irritation occurs. While administration with food may decrease GI absorption of doxycycline by up to 20%, administration on an empty stomach is generally not recommended due to GI intolerance. Of currently available tetracyclines, doxycycline has the least affinity for calcium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxycycline 20 mg tablet, Oracea, Apprilon [Canadian product]: Manufacturer states to take on an empty stomach 1 hour before or 2 hours after meals. Take with food if gastric irritation occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Periostat [Canadian product]: Manufacturer states to take at least 1 hour before morning and evening meals. Take with food if gastric irritation occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6473884\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, renal and liver function tests periodically with prolonged therapy. When used as part of alternative treatment for gonococcal infection, test of cure 7 days after dose (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Patients with no risk factors for chronic Q fever should undergo clinical and serological evaluation 6 months after diagnosis of acute Q fever to identify possible progression to chronic disease. Postpartum women treated during pregnancy for acute Q fever, others who are at high risk for progression to chronic disease or when used as part of treatment for chronic Q fever infection unrelated to endocarditis or vascular infection (eg, osteoarticular infections or chronic hepatitis), assess serologic response at 3, 6, 12, 18, and 24 months after diagnosis of acute Q fever (or after delivery in pregnant women) (CDC 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163291\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhibits protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria; may also cause alterations in the cytoplasmic membrane</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">20 mg tablets and capsules (Periostat [Canadian product]): Proposed mechanism: Has been shown to inhibit collagenase activity in vitro. Also has been noted to reduce elevated collagenase activity in the gingival crevicular fluid of patients with periodontal disease. Systemic levels do not reach inhibitory concentrations against bacteria.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163309\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Almost completely absorbed from the GI tract; average peak plasma concentration may be reduced ~20% (30% for Doryx MPC) by high-fat meal or milk</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Widely into body tissues and fluids including synovial, pleural, prostatic, seminal fluids, and bronchial secretions; saliva, aqueous humor, and CSF penetration is poor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not hepatic; partially inactivated in GI tract by chelate formation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Reduced at high pH; may be clinically significant in patients with gastrectomy, gastric bypass surgery or who are otherwise deemed achlorhydric</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 18 to 22 hours; End-stage renal disease: 18 to 25 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: Immediate release: 1.5 to 4 hours; delayed release: 2.8 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (30%); urine (23% to 40%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163312\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Doxycycline Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $653.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Oracea Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $769.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Doxycycline Hyclate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (50): $112.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (50): $307.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Doxycycline Monohydrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $155.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $1,691.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (50): $118.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $1,479.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Mondoxyne NL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $576.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (60): $912.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $631.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Morgidox Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $389.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $643.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Okebo Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $440.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Vibramycin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (50): $717.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Morgidox Combination)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 x 50 mg (1): $389.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 x 100 mg (1): $643.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 x 100 mg (1): $1,000.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Doxy 100 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $22.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Doxycycline Hyclate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $18.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Doxycycline Monohydrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/5 mL (60 mL): $26.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Vibramycin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/5 mL (60 mL): $49.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Vibramycin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (473 mL): $602.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Doryx MPC Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (30): $450.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Doryx Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (120): $1,565.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $2,897.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Doxycycline Hyclate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (120): $1,407.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (60): $613.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $1,314.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $1,759.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $2,605.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Acticlate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (60): $2,285.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $2,285.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Doxycycline Hyclate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $118.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (60): $1,871.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (50): $307.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $1,871.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Doxycycline Monohydrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $335.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $498.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (50): $246.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $274.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (TargaDOX Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $863.96</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163315\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abraxil (CL);</li>\n      <li>Agidox (LK);</li>\n      <li>Alldox (ZW);</li>\n      <li>Amermycin (HK, TH);</li>\n      <li>Apdox (BD);</li>\n      <li>Asdoxin (ET);</li>\n      <li>Azudoxat (DE);</li>\n      <li>Bactidox (PH);</li>\n      <li>Bassado (IT);</li>\n      <li>Biodoxi (IN);</li>\n      <li>Biomixin (MX);</li>\n      <li>By-Mycin (IE);</li>\n      <li>Ciclonal (MX);</li>\n      <li>Clordox (BR);</li>\n      <li>Cyclidox (ZA);</li>\n      <li>Cyclindox (VN);</li>\n      <li>Cytragen (PH);</li>\n      <li>Dagramycine (LU);</li>\n      <li>Dentacline (KR);</li>\n      <li>Dentistar (KR);</li>\n      <li>Deoxymykoin (CZ);</li>\n      <li>Doc-100 (TZ);</li>\n      <li>Docyl (TH);</li>\n      <li>Doinmycin (TW);</li>\n      <li>Dokat (TR);</li>\n      <li>Doksiciklin (HR);</li>\n      <li>Doksin (TR);</li>\n      <li>Doksybene (UA);</li>\n      <li>Domiken (MX);</li>\n      <li>Doryx (AU, NZ);</li>\n      <li>Dosil (ES);</li>\n      <li>Dotur (UY);</li>\n      <li>Doxat (BH, CY, EG, IQ, IR, JO, KW, LB, LY, MT, OM, QA, SA, SY, VN, YE);</li>\n      <li>Doxicap (ZW);</li>\n      <li>Doxiclat (ES);</li>\n      <li>Doximed (FI);</li>\n      <li>Doximycin (FI);</li>\n      <li>Doxin (PH, TH);</li>\n      <li>Doxine (NZ);</li>\n      <li>Doxipil (ES);</li>\n      <li>Doxiplus (PE);</li>\n      <li>Doxitin (LV);</li>\n      <li>Doxman (LK);</li>\n      <li>Doxsig (AU);</li>\n      <li>Doxxkam (PH);</li>\n      <li>Doxy (LB);</li>\n      <li>Doxy 200 (LU);</li>\n      <li>Doxy A (BD);</li>\n      <li>Doxy Komb (LU);</li>\n      <li>Doxy M (EE);</li>\n      <li>Doxy SMB (LU);</li>\n      <li>Doxy-1 (IN);</li>\n      <li>Doxy-100 (DE, NZ);</li>\n      <li>Doxybene (CZ);</li>\n      <li>Doxycap (HK, SG);</li>\n      <li>Doxycin (SA);</li>\n      <li>Doxyclin (ZW);</li>\n      <li>Doxycline (LU, TH);</li>\n      <li>Doxycyclin AL (HU);</li>\n      <li>Doxycycline (BE);</li>\n      <li>Doxycycline-Ethypharm (LU);</li>\n      <li>Doxycycline-Eurogenerics (LU);</li>\n      <li>Doxydar (JO, QA, SA);</li>\n      <li>Doxyhexal (CZ, HU, LU);</li>\n      <li>Doxylag (BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);</li>\n      <li>Doxylan (LV);</li>\n      <li>Doxylcap (TH);</li>\n      <li>Doxylets (LU);</li>\n      <li>Doxylin (AU, IL, NO, NZ);</li>\n      <li>Doxyline (SG);</li>\n      <li>Doxylis (FR);</li>\n      <li>Doxymycin (TW, ZA);</li>\n      <li>Doxymycine (LU);</li>\n      <li>Doxypharm (HU);</li>\n      <li>Dumoxin (BH, CY, EG, ID, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Duo Di (CN);</li>\n      <li>Duradox (AE, KW, QA);</li>\n      <li>Efracea (GB, IE);</li>\n      <li>Empadoxine (ET);</li>\n      <li>Etidoxina (CO);</li>\n      <li>Genobiotic-Doxi (MX);</li>\n      <li>Grandoxy (AE, QA);</li>\n      <li>Granudoxy (FR, LU);</li>\n      <li>Hiramicin (HR);</li>\n      <li>Impedox (BD);</li>\n      <li>Interdoxin (ID);</li>\n      <li>Lenteclin (ET);</li>\n      <li>Madoxy (TH);</li>\n      <li>Mardox (BD);</li>\n      <li>Medomycin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SG, SL, SN, TH, TN, TW, TZ, UG, ZM, ZW);</li>\n      <li>Medox (PH);</li>\n      <li>Microdox (LK, ZW);</li>\n      <li>Miraclin (IT);</li>\n      <li>Monocin (KR);</li>\n      <li>Monodox (CO);</li>\n      <li>Oracea (ES);</li>\n      <li>Periostat (GB);</li>\n      <li>Policycline (TH);</li>\n      <li>Radox (BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Remycin (MT, TR, TW);</li>\n      <li>Retadox (LB);</li>\n      <li>Retens (MT);</li>\n      <li>Revidox (LK);</li>\n      <li>Servidoxine (EC);</li>\n      <li>Siadocin (TH);</li>\n      <li>Sigadoxin (PT);</li>\n      <li>Supracyclin (AT, CH, PE);</li>\n      <li>Supramycina (EC, PY);</li>\n      <li>Tabocine (AE, QA);</li>\n      <li>Tarocin (KW);</li>\n      <li>Tarocine (BH);</li>\n      <li>Tedoxy (PH);</li>\n      <li>Tenutan (BB, BM, BS, BZ, GY, JM, SR, TT);</li>\n      <li>Teradox (PH);</li>\n      <li>Teradoxin (ET);</li>\n      <li>Tolexine (FR, HK);</li>\n      <li>Tolexine Ge (FR);</li>\n      <li>Torymycin (TH);</li>\n      <li>Tremesal (VE);</li>\n      <li>Unidox (BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, PL, QA, RO, SA, SY, YE);</li>\n      <li>Unidoxy (KR);</li>\n      <li>Veemycin (TH);</li>\n      <li>Verboril (AR);</li>\n      <li>Vibradox (DK, PT);</li>\n      <li>Vibramicina (AR, CL, CO, MX, PE, PT, UY, VE);</li>\n      <li>Vibramitsyn (UA);</li>\n      <li>Vibramycin (AE, AT, AU, BB, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CY, DE, EG, ET, GB, GH, GM, GN, GR, GY, HK, HU, ID, IE, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, OM, PH, PK, QA, RU, SA, SC, SD, SE, SL, SN, SR, SY, TH, TN, TT, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Vibramycin N (KR);</li>\n      <li>Vibramycine (FR);</li>\n      <li>Vibratab (BE, LU);</li>\n      <li>Vibraveineuse (FR);</li>\n      <li>Vibravenos (AT, DE);</li>\n      <li>Viclorax (PE);</li>\n      <li>Vidoxy (KR);</li>\n      <li>Vivradoxil (MX);</li>\n      <li>Weibamycin (TW);</li>\n      <li>Withamycin (TW);</li>\n      <li>Yong Xi (CN);</li>\n      <li>Zadorin (BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy</i>, 16th ed, New York, NY: Medical Letter, 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19384149\"></a>ACOG Committee on Practice Bulletins--Gynecology. ACOG practice bulletin No. 104: antibiotic prophylaxis for gynecologic procedures. <i>Obstet Gynecol</i>. 2009;113(5):1180-1189. doi: 10.1097/AOG.0b013e3181a6d011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/19384149/pubmed\" target=\"_blank\" id=\"19384149\">19384149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Acticlate (doxycycline hyclate) [prescribing information]. Exton, PA: Aqua Pharmaceuticals; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adoxa (doxycyline) [prescribing information]. Melville, NY: PharmaDerm; February 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ailani RK, Agastya G, Ailani RK, et al, &ldquo;Doxycycline is a Cost-Effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia,&rdquo; <i>Arch Intern Med</i>, 1999, 159(3):266-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/9989538/pubmed\" target=\"_blank\" id=\"9989538\">9989538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics. Doxycycline. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, ed. R<i>ed Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. <i>MMWR Recomm Rep</i>. 2013;62(RR-03):1-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/23535757/pubmed\" target=\"_blank\" id=\"23535757\">23535757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO. Drug use during breast-feeding. <i>Clin Pharm</i>. 1991;10(8):594-624.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/1934918/pubmed\" target=\"_blank\" id=\"1934918\">1934918</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arguin PM, Tan KR. Infectious diseases related to travel: malaria. In: CDC Health Information for International Travel 2016. Centers for Disease Control and Prevention (CDC). <a href=\"https://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/malaria#4661\">https://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/malaria#4661</a>. Updated July 10, 2015. Accessed March 14, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ariza J, Bosilkovski M, Cascio A, et al; International Society of Chemotherapy Institute of Continuing Medical Education of Ioannina. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. <i>PLoS Med</i>. 2007;4(12):e317.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/18162038/pubmed\" target=\"_blank\" id=\"18162038\">18162038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari E, Baddour LM. Prosthetic joint infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 12, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States. <i>MMWR Recomm Rep</i>. 2016;65(2):1-44. doi: 10.15585/mmwr.rr6502a1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/27172113/pubmed\" target=\"_blank\" id=\"27172113\">27172113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    B&ouml;cker R, M&uuml;hlberg W, Platt D, et al, &ldquo;Serum Level, Half-Life and Apparent Volume of Distribution of Doxycycline in Geriatric Patients,&rdquo; <i>Eur J Clin Pharmacol</i>, 1986, 30(1):105-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/3709622/pubmed\" target=\"_blank\" id=\"3709622\">3709622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bosilkovski M. Clinical manifestations, diagnosis, and treatment of brucellosis. Calderwood S, Edwards MS, eds. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 9, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bryant SG, Fisher S, and Kluge RM, &ldquo;Increased Frequency of Doxycycline Side Effects,&rdquo; <i>Pharmacotherapy</i>, 1987, 7(4):125-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/3684731/pubmed\" target=\"_blank\" id=\"3684731\">3684731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Diagnosis and Management of Q Fever -- United States, 2013: Recommendations from CDC and the Q Fever Working Group,&quot; <i>MMWR Recomm Rep</i>, 2013, 62(RR03):1-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/23535757/pubmed\" target=\"_blank\" id=\"23535757\">23535757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States, Treatment Table Update,&quot; July 1, 2013. Available at <a href=\"http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf\" target=\"_blank\">http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Q Fever - California, Georgia, Pennsylvania, and Tennessee, 2000-2001,&quot; <i>MMWR Weekly</i>, 2002, 51(41):924-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/12403408/pubmed\" target=\"_blank\" id=\"12403408\">12403408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Recommended antibiotic treatment for plague. 2015. Available at <a href=\"https://www.cdc.gov/plague/healthcare/clinicians.html\" target=\"_blank\">https://www.cdc.gov/plague/healthcare/clinicians.html</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Use of Anthrax Vaccine in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009,&quot; <i>MMWR</i>, 2010, 59(6):1-30. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5906a1.htm?s_cid=rr5906a1_e\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5906a1.htm?s_cid=rr5906a1_e</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/20651644/pubmed\" target=\"_blank\" id=\"20651644\">20651644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Update: Investigation of Bioterrorism-Related Anthrax and Interim Guidelines for Exposure Management and Antimicrobial Therapy, October 2001,&rdquo; <i>MMWR</i>, October 26, 2001, 50(42):909-19. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/11699843/pubmed\" target=\"_blank\" id=\"11699843\">11699843</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo; <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, and Blumer JL, &quot;Antibiotics and Breast-Feeding: A Critical Review of the Literature,&quot; <i>Paediatr Drugs</i>, 2002, 4(12):817-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/12431134/pubmed\" target=\"_blank\" id=\"12431134\">12431134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daunt N, Brodribb TR, and Dickey JD, &ldquo;Oesophageal Ulceration Due to Doxycycline,&rdquo; <i>Br J Radiol</i>, 1985, 58(696):1209-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/3842633/pubmed\" target=\"_blank\" id=\"3842633\">3842633</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daya M and Nakamura Y, &quot;Pulmonary Disease From Biological Agents: Anthrax, Plague, Q Fever, and Tularemia,&quot; <i>Crit Care Clin</i>, 2005, 21(4):747-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/16168313/pubmed\" target=\"_blank\" id=\"16168313\">16168313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11386933\"></a>Dennis DT, Inglesby TV, Henderson DA, et al; Working Group on Civilian Biodefense. Tularemia as a biological weapon: medical and public health management. <i>JAMA</i>. 2001;285(21):2763-2773.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/11386933/pubmed\" target=\"_blank\" id=\"11386933\">11386933</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doryx (doxycycline hyclate) [prescribing information]. Greenville, NC: Mayne Pharma; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doryx MPC (doxycycline hyclate delayed release tablets) [prescribing information]. Greenville, NC: Mayne Pharma USA; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doryx MPC (doxycycline hyclate delayed-release tablets) [prescribing information]. Greenville, NC: Mayne Pharma USA; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doxycycline hyclate delayed-release tablets [prescribing information]. Greenville, NC: Mayne Pharma; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doxycycline hyclate tablets (equivalent to 20 mg doxycycline) [prescribing information]. Philadelphia, PA: Lannett Company; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doxy 100 injection (doxycycline) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eyre RC. Evaluation of acute scrotal pain in adults. O'Leary MP, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 9, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fenollar F, Fournier PE, Carrieri MP, et al, &quot;Risks Factors and Prevention of Q Fever Endocarditis,&quot; <i>Clin Infect Dis</i>, 2001, 33(3):312-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/11438895/pubmed\" target=\"_blank\" id=\"11438895\">11438895</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foucault C, Raoult D, Brouqui P. Randomized open trial of gentamicin and doxycycline for eradication of Bartonella quintana from blood in patients with chronic bacteremia. <i>Antimicrob Agents Chemother</i>. 2003;47(7):2204-2207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/12821469/pubmed\" target=\"_blank\" id=\"12821469\">12821469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Francke EL and Neu HC, &ldquo;Chloramphenicol and Tetracyclines,&rdquo; <i>Med Clin North Am</i>, 1987, 71(6):155-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/3320617/pubmed\" target=\"_blank\" id=\"3320617\">3320617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halperin JJ, Shapiro ED, Logigian E, et al, &ldquo;Practice Parameter: Treatment of Nervous System Lyme Disease (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology,&quot; <i>Neurology</i>, 2007, 69(1):91-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/17522387/pubmed\" target=\"_blank\" id=\"17522387\">17522387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harper M. Clinical manifestations and initial management of animal and human bites. Danzl DF, Wolfson AB, eds. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 9, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. <i>Ann Intern Med</i>. 2016;164(6):425-434. doi: 10.7326/M15-1840.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/26785402/pubmed\" target=\"_blank\" id=\"26785402\">26785402</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hartzell JD, Wood-Morris RN, Martinez LJ, et al, &quot;Q Fever: Epidemiology, Diagnosis, and Treatment,&quot; <i>Mayo Clin Proc</i>, 2008, 83(5):574-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/18452690/pubmed\" target=\"_blank\" id=\"18452690\">18452690</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hasanjani Roushan MR, Mohraz M, Hajiahmadi M, Ramzani A, Valayati AA. Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. <i>Clin Infect Dis</i>. 2006;42(8):1075-1080.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/16575723/pubmed\" target=\"_blank\" id=\"16575723\">16575723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health and Human Services [HHS] Panel on Opportunistic Infections [OI] in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health and Human Services [HHS] Panel on Opportunistic Infections [OI] in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated October 18, 2017. Accessed October 23, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24447897\"></a>Hendricks KA, Wright ME, Shadomy SV, et al. Center for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. <i>Emerg Infect Dis</i>. 2014;20(2):e130687.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/24447897/pubmed\" target=\"_blank\" id=\"24447897\">24447897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hicks CB, Clement M. Syphilis: Treatment and monitoring. Hynes NA, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 9, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hu L. Treatment of Lyme disease. Steere AC, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 9, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inglesby TV, Dennis DT, Henderson DA, et al, &quot;Plague as a Biological Weapon: Medical and Public Health Management. Working Group on Civilian Biodefense,&quot; <i>JAMA</i>, 2000, 283(17):2281-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/10807389/pubmed\" target=\"_blank\" id=\"10807389\">10807389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jia B, Zhang F, Pang P, et al. Brucella endocarditis: Clinical features and treatment outcomes of 10 cases from Xinjiang, China. <i>J Infect</i>. 2017;74(5):512-514. doi: 10.1016/j.jinf.2017.01.011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/28143754/pubmed\" target=\"_blank\" id=\"28143754\">28143754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jolkovsky DL and Ciancio S, &quot;Chemotherapeutic Agents,&quot; Newman MG, Takei HH, Klokkevold PR, et al, eds, <i>Clinical Periodontology</i>, 10th ed, St Louis, MO: Saunders/Elsevier, 2006, 802-3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joshi N and Miller DQ, &ldquo;Doxycycline Revisited,&rdquo; <i>Arch Intern Med</i>, 1997, 157(13):1421-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/9224219/pubmed\" target=\"_blank\" id=\"9224219\">9224219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kanafani ZA. Invasive Cutibacterium (formerly Propionibacterium) infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 12, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. <i>Drugs</i>. 2013;73(8):779-787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/23657872/pubmed\" target=\"_blank\" id=\"23657872\">23657872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kvale PA, Selecky, Prakash BS, et al, &ldquo;Palliative Care In Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition),&rdquo; <i>Chest</i>, 2007, 132(Suppl 3):268-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/17873181/pubmed\" target=\"_blank\" id=\"17873181\">17873181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections in adults and children: executive summary. <i>Clin Infect Dis</i>. 2011;52(3):285-292.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ljungberg B and Nilsson-Ehle I, &ldquo;Pharmacokinetics of Antimicrobial Agents in the Elderly,&rdquo; <i>Rev Infect Dis</i>, 1987, 9(2):250-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/3296097/pubmed\" target=\"_blank\" id=\"3296097\">3296097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maier LE. Management of rosacea. Dahl MV, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 9, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandell LA, Wunderink RG, Anzueto A, et al, &ldquo;Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines On The Management Of Community-Acquired Pneumonia In Adults,&rdquo; 2007, <i>Clin Infect Dis</i>, 44(Suppl 2):27-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marrazzo J. Treatment of Chlamydia trachomatis infection. Hynes NA, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 9, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Million M, Walter G, Thuny F, Habib G, Raoult D. Evolution from acute Q fever to endocarditis is associated with underlying valvulopathy and age and can be prevented by prolonged antibiotic treatment. <i>Clin Infect Dis</i>. 2013;57(6):836-844. doi: 10.1093/cid/cit419.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/23794723/pubmed\" target=\"_blank\" id=\"23794723\">23794723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monodox (doxycycline) [prescribing information]. Exton, PA: Aqua Pharmaceuticals; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monodoxyne NL (doxycycline) [prescribing information]. Petaluma, CA: IntraDerm Pharmaceuticals; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):e1-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/24528911/pubmed\" target=\"_blank\" id=\"24528911\">24528911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mylonas I, &quot;Antibiotic Chemotherapy During Pregnancy and Lactation Period: Aspects for Consideration,&quot; <i>Arch Gynecol Obstet</i>, 2011, 283(1):7-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/20814687/pubmed\" target=\"_blank\" id=\"20814687\">20814687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oracea [prescribing information]. Fort Worth, TX: Galderma Laboratories LP; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Penn RL. Clinical manifestations, diagnosis, and treatment of tularemia. Calderwood SB, Edwards, MS, eds. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 9, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16404570\"></a>Porcel JM, Salud A, Nabal M, et al, &ldquo;Rapid Pleurodesis With Doxycycline Through a Small-Bore Catheter for the Treatment of Metastatic Malignant Effusions,&rdquo; <i>Support Care Cancer</i>, 2006, 14(5):475-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/16404570/pubmed\" target=\"_blank\" id=\"16404570\">16404570</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pugashetti R, Shinkai K. Treatment of acne vulgaris in pregnant patients. <i>Dermatol Ther</i>. 2013;26(4):302-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/23914887/pubmed\" target=\"_blank\" id=\"23914887\">23914887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rams TE and Slots J, &ldquo;Antibiotics in Periodontal Therapy: An Update,&rdquo; <i>Compendium</i>, 1992, 13(12):1130, 1132, 1134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/1298559/pubmed\" target=\"_blank\" id=\"1298559\">1298559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raoult D. Treatment and prevention of Q fever. Sexton DJ, Edwards MS, eds. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 9, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8494419\"></a>Robinson LA, Fleming WH, Galbraith TA. Intrapleural doxycycline control of malignant pleural effusions. <i>Ann Thorac Surg</i>. 1993;55(5):1115-1121; discussion 1121-1122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/8494419/pubmed\" target=\"_blank\" id=\"8494419\">8494419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommendations for treatment of human infections caused by Bartonella species. <i>Antimicrob Agents Chemother</i>. 2004;48(6):1921-1933.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/15155180/pubmed\" target=\"_blank\" id=\"15155180\">15155180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ross J, Judlin P, and Nilas L, &ldquo;European Guideline for the Management of Pelvic Inflammatory Disease,&quot; Int J STD AIDS, 2007, 18(10):662-6. Available at http://std.sagepub.com/content/18/10/662.full.pdf+html. Accessed May 15, 2013.17945043</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saivin S and Hovin G, &ldquo;Clinical Pharmacokinetics of Doxycycline and Minocycline,&rdquo; <i>Clin Pharmacokinet</i>, 1985, 15:355-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/3072140/pubmed\" target=\"_blank\" id=\"3072140\">3072140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanchez J, Somolinos AL, Almod&oacute;var PI, Webster G, Bradshaw M, Powala C. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. <i>J Am Acad Dermatol</i>. 2005;53(5):791-797.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/16243127/pubmed\" target=\"_blank\" id=\"16243127\">16243127</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sexton DJ. Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection). Calderwood SB, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 27, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sexton DJ, McClain MT. Treatment of Rocky Mountain spotted fever. Calderwood SB, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 9, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simoff MJ, Lally B, Slade MG, et al. Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2013;143(5 suppl):e455S-e497S. doi: 10.1378/chest.12-2366.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/23649452/pubmed\" target=\"_blank\" id=\"23649452\">23649452</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. <i>BMJ</i>. 2008;336(7646):701-704. doi: 10.1136/bmj.39497.500903.25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/18321957/pubmed\" target=\"_blank\" id=\"18321957\">18321957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smilack JD, Wilson WR, and Cockerill FR 3d, &ldquo;Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole,&rdquo; <i>Mayo Clin Proc</i>, 1991, 66(12):1270-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/1749296/pubmed\" target=\"_blank\" id=\"1749296\">1749296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smiley CJ, Tracy SL, Abt E, et al. Evidence-based clinical practice guideline on the nonsurgical treatment of chronic periodontitis by means of scaling and root planing with or without adjuncts. <i>J Am Dent Assoc</i>. 2015;146(7):525-535. doi: 10.1016/j.adaj.2015.01.026.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/26113100/pubmed\" target=\"_blank\" id=\"26113100\">26113100</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spach DH. Endocarditis caused by Bartonella. Calderwood SB, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 9, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tokuda G, Yuasa M, Mihara S et al. Clinical study of doxycycline in obstetrical and gynecological fields. <i>Chemotherapy (Tokyo)</i>. 1969;17:339-344. Available at <a href=\"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+100\" target=\"_blank\">http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+100</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vibramycin (doxycycline oral) [prescribing information]. New York; NY: Pfizer; received August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vibramycin (doxycycline injection) [prescribing information]. New York; NY: Pfizer; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vibramycin Capsules (doxycycline) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiesenfeld HC. Pelvic inflammatory disease: Treatment. Hynes NA, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 9, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson WR and Cockerill FR 3d, &ldquo;Tetracyclines, Chloramphenicol, Erythromycin, and Clindamycin,&rdquo; <i>Mayo Clin Proc</i>, 1987, 62(10):906-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/3657308/pubmed\" target=\"_blank\" id=\"3657308\">3657308</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/24528911</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al, &ldquo;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2006, 43(9):1089-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wyler DJ, &ldquo;Malaria: Overview and Update,&rdquo; <i>Clin Infect Dis</i>, 1993, 16(4):449-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/8513046/pubmed\" target=\"_blank\" id=\"8513046\">8513046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf. Accessed May 17, 2016.26897386</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenilman JM. Lymphogranuloma venereum. Hynes NA, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 9, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zheng N, Wang W, Zhang JT, Cao Y, Shao L, Jiang JJ, Huang XS, Tian CL, Yu SY. Neurobrucellosis. <i>Int J Neurosci</i>. 2017:1-8. doi: 10.1080/00207454.2017.1363747.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-drug-information/abstract-text/28768443/pubmed\" target=\"_blank\" id=\"28768443\">28768443</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9393 Version 307.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F163331\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F163332\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F163364\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F163336\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F163349\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F163337\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F163338\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15804929\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F163303\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F163288\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F23449398\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F20303059\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F163306\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F163304\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25473208\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F163372\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F163295\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F163310\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F163292\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F163358\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F163297\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F163326\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F163300\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F163313\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3415107\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F163314\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6473884\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F163291\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F163309\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F163312\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F163315\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9393|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=doxycycline-patient-drug-information\" class=\"drug drug_patient\">Doxycycline: Patient drug information</a></li><li><a href=\"topic.htm?path=doxycycline-pediatric-drug-information\" class=\"drug drug_pediatric\">Doxycycline: Pediatric drug information</a></li></ul></div></div>","javascript":null}